Verrica Pharmaceuticals Inc.
VRCA
$6.11
-$0.04-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2,846.72% | -234.31% | 102.09% | 39.87% | 29.13% |
| Total Depreciation and Amortization | 3.26% | -7.54% | -4.33% | -17.79% | -26.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.24% | 58.79% | -19.61% | -63.71% | 35.24% |
| Change in Net Operating Assets | -74.69% | 168.35% | -153.10% | -12.10% | -137.12% |
| Cash from Operations | -147.40% | 196.43% | 20.77% | 21.08% | -87.71% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 150.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -803.77% | 4.12% | -2.42% | -984.76% | -72.35% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -1,401.11% |
| Cash from Financing | 442.39% | 4.12% | -2.42% | -110.29% | 10,030.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.74% | 140.15% | 15.15% | -171.60% | 360.51% |